articleTop 1% cited

A long-term follow-up study of mortality in transsexuals receiving treatment with cross-sex hormones

European Journal of Endocrinology · 2011 · Vol. 164(4) · pp. 635–642

Henk Asscheman✉Erik J. Giltay(Leiden University Medical Center)Jos Megens(Amsterdam UMC Location VUmc)W de RondeMichael A. A. van Trotsenburg(Amsterdam UMC Location VUmc)Louis Gooren

View via DOI Publisher page

Abstract

The increased mortality in hormone-treated MtF transsexuals was mainly due to non-hormone-related causes, but ethinyl estradiol may increase the risk of cardiovascular death. In the FtM transsexuals, use of testosterone in doses used for hypogonadal men seemed safe.

LGBTQ Health, Identity, and Policy Hormonal and reproductive studies Sexual Differentiation and DisordersMedicineTestosterone (patch)PopulationCyproterone acetateHormoneSex hormone-binding globulinMortality rateEstrogenInternal medicineCohort

MeSH terms

AdolescentAdultAgedCyproteroneEthinyl EstradiolFemaleFollow-Up StudiesHumansMaleMiddle AgedGonadal Steroid HormonesTestosteroneTranssexualismCyproterone AcetateYoung Adult

Citations

557

FWCI

22.36

field-weighted impact

References

Percentile

100%

vs. same field & year

Citations per year

Cited by

Prevalence of cardiovascular disease and cancer during cross-sex hormone therapy in a large cohort of trans persons: a case–control study